End-to-end specialty drug access automation (intake → benefits → OOP estimate → PA) vs point solutions—what’s working in 2026?

Most specialty-drug leaders walked into 2026 with the same reality: you’ve bought “automation” three times, but prior auth queues are still full, benefits verifications still live in payer portals and phone trees, and your team still spends mornings digging through faxes. The real debate now isn’t “AI or not?”—it’s whether you bet on end-to-end specialty drug access automation (intake → benefits → OOP estimate → prior auth) or keep stitching together point solutions for each step.

As someone who’s owned the numbers on both sides—manual workflows, bolt-on tools, and now agentic, end-to-end automation—here’s how I’d rank your options in 2026.

Quick Answer: The best overall choice for automating specialty drug access end‑to‑end is Mandolin. If your priority is narrowly optimizing a single step like benefits verification or prior auth, step‑specific point solutions can be a fit. For teams experimenting with in‑house automation before committing to full transformation, internal RPA/scripts are the most flexible—but also the most fragile.

At-a-Glance Comparison

Rank	Option	Best For	Primary Strength	Watch Out For
1	Mandolin (end-to-end agents)	High-volume infusion & specialty-drug programs that need full intake → benefits → OOP → PA automation	Executes the entire back office across portals, faxes, and phone calls with logged, traceable actions	Requires organizational readiness to standardize on one end-to-end operating model
2	Step-specific point solutions	Teams wanting targeted relief (e.g., just ePA, just eligibility checks) without touching the broader workflow	Deep feature depth in a single slice (ePA, eligibility, document capture)	Fragmentation between tools, handoffs back to staff, and gaps in “messy middle” work
3	Internal RPA / scripting	Large systems with strong IT/analytics teams testing automation on narrow, repetitive tasks	Customizable for very static processes in a single system	Brittle with payer/portal changes; doesn’t handle faxes/phones well; high maintenance burden

Comparison Criteria

We evaluated each approach against the realities that actually move the needle in 2026:

• End-to-end coverage of the access lifecycle: Can it truly handle intake → benefits → out-of-pocket estimates → medical policy review → prior authorization → claims follow-up, or does work fall back to staff at each seam?
• Channel realism (portals, faxes, phones): Does it work only when clean APIs and structured data exist, or can it operate in payer portals, read faxes, and make calls the way your back office actually does?
• Operational and financial impact: Does it measurably reduce minutes per referral, backlog days, denials, and FTE load while improving time to therapy and margin accuracy (site-specific fee schedules, GPO/340B, co-pay assistance), with traceable, compliant actions?

---

Detailed Breakdown

1. Mandolin (Best overall for high-volume, end-to-end specialty drug access)

Mandolin ranks as the top choice because it behaves like a full back office of your best specialists, executing the entire specialty-drug access workflow—intake through prior auth and claims follow-up—across portals, faxes, and phone calls.

What it does well:

• End-to-end execution, not just data movement:
  Mandolin doesn’t stop at “capturing” or “routing” data. Its AI agents:

  • Read and interpret referral forms, lab reports, and clinical notes regardless of format or source, then enter the right fields into your EHR.
  • Perform full benefits investigations in payer portals, just like a trained specialist—checking medical and pharmacy benefits, site-of-care rules, and coverage nuances.
  • Calculate precise out-of-pocket estimates by factoring in site-specific fee schedules, drug acquisition costs, GPO and 340B pricing, and available co-pay assistance.
  • Compare payer medical policy requirements to the chart, assemble the correct clinical package, and submit prior auths through the channels payers actually require (portals, fax, or phone).
  • Track claim status and trigger appeals, checking portals or calling payers and interpreting remits so you’re not burning hours on status calls.

• Channel-native automation (no APIs required):
  Where many “AI platforms” still need clean interfaces, Mandolin is built for the messy middle:

  • Navigates payer portals directly.
  • Reads inbound faxes and scanned PDFs.
  • Makes outbound calls when the portal stops short.
  • Logs every action so you can audit how a decision was made and stay aligned with payer and regulatory requirements.
    When Mandolin says “workflows, not widgets,” it means the work actually gets done where it lives today, not in an idealized integration diagram.

• Proven, quantified impact at scale:
  Mandolin’s published results are unusually concrete for this space:

  • 24x increase in speed: moving from ~20 minutes per document manually to about 3 minutes with an under‑2‑hour turnaround.
  • A national ambulatory infusion center eliminated a 4-day prescription backlog to zero and scaled to 4,500+ patients/month, while refocusing 13 outsourced FTEs on complex, high-value work instead of repetitive tasks.
  • Teams report faster time-to-therapy alongside reduced denials and revenue leakage—because benefits, OOP estimates, and PAs are consistently built on payer policy and accurate economics.

Tradeoffs & Limitations:

• Requires commitment to an operating-model shift:
  Mandolin works best when you aren’t treating it as just another “tool in the stack,” but as your primary back-office execution layer. That means:
  • Aligning SOPs around the agentic workflow (e.g., letting Mandolin own intake + benefits + PA instead of splitting those steps across three teams).
  • Being ready to measure performance in minutes, days, and denials avoided, not just “logins” or “tasks completed.” For teams just looking to bolt on another widget to an already fragmented process, Mandolin’s end-to-end approach may feel like “too much” at first—even though that’s where the biggest gains come from.

Decision Trigger:
Choose Mandolin if you want to collapse your entire specialty-drug access workflow into a single, compliant, AI-driven back office—with documented proof like 24x speed, zero backlog, and the ability to scale to thousands of patients per month without adding headcount.

---

2. Step-specific point solutions (Best for targeted relief on a single step)

Step-specific point solutions—think ePA tools, benefits eligibility APIs, or document-capture systems—are the strongest fit when your goal is to relieve pressure at one obvious bottleneck without rethinking the full workflow.

What they do well:

• Deep functionality in a narrow lane:
  Point solutions shine when:

  • You need electronic prior authorization for plans and drugs that fit ePA standards.
  • You want quick eligibility checks for basic coverage questions.
  • You’re trying to digitize inbound documents into structured fields.
    They often come with well-polished UIs, role-based workflows, and specialty features within that one step.

• Lower perceived switching cost:
  Because they focus on a single slice, they can be easier to pilot:

  • Minimal workflow change for staff (“Use this tool for ePA, everything else stays the same”).
  • Less organizational debate versus an end-to-end transformation. For teams early in their automation journey, this can feel like a safe first move.

Tradeoffs & Limitations:

• Fragmentation and manual handoffs:
  In real specialty-drug ops, the access journey isn’t a straight API chain—it’s a loop across faxes, portals, and phones. Point solutions tend to:

  • Hand work back to humans when data is messy, documents are incomplete, or the payer isn’t supported.
  • Require staff to swivel between multiple systems—one for intake, another for eligibility, another for ePA, another for financial counseling—rebuilding context in each.
  • Leave gaps: ePA doesn’t help when the payer requires a PDF faxed with specific notes and labs; an eligibility API doesn’t check the portal nuance that actually decides coverage.

• Limited impact on backlog days and staffing math:
  Because the whole workflow is still fragmented:

  • Your fax-to-EHR lag still exists if only one step is automated.
  • Prior auth packaging still depends on someone understanding policy and assembling documents.
  • Claims follow-up still burns hours on calls and portal checks.
    You might shave minutes off a step, but you rarely see the kind of 24x speed, zero‑day backlog, and FTE-redeployment gains that come from true end-to-end execution.

Decision Trigger:
Choose step-specific point solutions if you have a clearly isolated pain point (e.g., ePA for a limited subset of payers) and you’re not yet ready to bet on a single end-to-end operating model. Expect incremental relief, not a fundamentally different access engine.

---

3. Internal RPA / scripting (Best for controlled pilots on narrow, repetitive tasks)

Internal RPA/scripts stand out for organizations with strong IT and analytics teams that want to experiment with automation on tightly defined workflows before engaging a specialized partner.

What they do well:

• Highly customized for a specific, static task:
  Internal teams can:

  • Script data movement between two systems that rarely change.
  • Automate basic clicks in a single web app.
  • Build simple rules-based bots for predictable tasks (e.g., moving a clean PDF from one folder into a system). This can offload some keystrokes on the most repetitive parts of a workflow.

• Full control over configuration and governance:
  You own the code, logic, and deployment:

  • Governance and security can be tailored to your risk posture.
  • You decide the level of logging, oversight, and rollback.

Tradeoffs & Limitations:

• Brittle in the face of real-world change:
  Specialty-drug workflows don’t stay static:

  • Payer portals update layouts, add fields, or change navigation—breaking click-path scripts.
  • Medical policy criteria evolve, requiring nuanced interpretation of charts, not simple rules.
  • Fax formats change based on referring practices and EMR templates.
    Maintaining a fleet of scripts to keep up with that reality becomes its own FTE load. And pure RPA struggles with phone-based work and unstructured documents.

• Doesn’t deliver true end-to-end coverage:
  Even in the best-case scenario, internal automation rarely:

  • Reads and interprets complex clinical notes and labs with the nuance of a trained specialist.
  • Calculates OOP using site-specific fee schedules, drug acquisition costs, GPO/340B, and co-pay programs.
  • Submits PAs through every required channel (portal, fax, phone) and then chases claim status and appeals.
    You end up with pockets of automation surrounded by manual work—the same fragmentation problem, just with homegrown tooling.

Decision Trigger:
Choose internal RPA/scripts if you have a strong internal automation team, a very narrow, stable process to target, and you’re explicitly treating it as a learning or interim step—not your long-term answer for specialty-drug access.

---

Final Verdict

In 2026, what’s actually working for specialty-drug access isn’t generic “AI,” it’s the ability to execute the full back-office workflow end-to-end—intake → benefits → OOP estimate → prior auth, plus claims statusing and appeals—inside the messy channels where the work really happens.

• If your goal is to truly move the needle on time to therapy, backlog days, denials, and FTE needs, end-to-end specialty drug access automation with Mandolin is the only option that behaves like a back office instead of a dashboard. The results—24x faster document handling, zero backlogs, thousands of patients per month, and refocused staff—are the kind of outcomes operators actually feel.
• If you’re only ready for a small, step-level upgrade, point solutions can buy relief at a single choke point, but you should go in knowing they won’t fix the “messy middle” where most breakdowns happen.
• If you’re experimenting with internal automation, treat it as a pilot to build internal understanding, not a substitute for a purpose-built, agentic back office that can keep up with payer complexity, unstructured docs, and constant change.

The organizations winning specialty-drug access in 2026 are the ones standardizing on an end-to-end engine that does the work—not just moves the data—and can prove its impact in minutes, days, and FTE equivalents.

Next Step

Get Started